1. Home
  2. |Professionals
  3. |Greg Ikonen

Greg Ikonen

Partner | He/Him/His
Partner | He/Him/His
Z2lrb25lbkBjcm93ZWxsLmNvbQ==
VCardLinkedIn
VCardLinkedIn

Areas of Focus

Overview

Greg Ikonen is chair of Crowell’s Life Sciences practice. He has spent more than 20 years advising biotech companies on corporate and complex transactional matters, including structuring and negotiating strategic R&D collaborations, interactions with academic institutions, board governance, and venture and non-dilutive financings. His mix of business and legal in-house experience enables him to provide pragmatic, business-focused solutions to intricate challenges faced by life sciences companies.

Earlier in his career, Greg served as Chief Executive Officer of Mendel Biotechnology, Inc., where he led the successful sale of its operating business, and subsequently led the team after the acquisition in building out its microbial platform and development of new microbial products.

Greg’s representative clients include The Bluefield Project to Cure FTD, IDEAYA Biosciences, and Tasca Therapeutics.

Career & Education

    • Chief Executive Officer, Mendel Biotechnology, Inc.
      • Led the successful sale of its operating business, and subsequently led the team after the acquisition in building out its microbial platform and development of new microbial products.
      • Served as Senior Vice President, Corporate Development, where he developed the business case and strategy for the microbial-focused technology platform that drove the acquisition.
      • Served as the company’s General Counsel, advising on corporate governance matters, successfully completing equity and R&D financings, negotiating collaboration agreements with BP, Bayer Crop Sciences and the Monsanto Company, and overseeing regulatory matters, including representing the company in the BIO trade association.
      • Served as General Counsel for a venture-backed biologics company developing therapies for respiratory diseases.
    • Partner, AmLaw 100 firmFocused on licensing and strategic collaborations for life sciences and technology companies.
    • Chief Executive Officer, Mendel Biotechnology, Inc.
      • Led the successful sale of its operating business, and subsequently led the team after the acquisition in building out its microbial platform and development of new microbial products.
      • Served as Senior Vice President, Corporate Development, where he developed the business case and strategy for the microbial-focused technology platform that drove the acquisition.
      • Served as the company’s General Counsel, advising on corporate governance matters, successfully completing equity and R&D financings, negotiating collaboration agreements with BP, Bayer Crop Sciences and the Monsanto Company, and overseeing regulatory matters, including representing the company in the BIO trade association.
      • Served as General Counsel for a venture-backed biologics company developing therapies for respiratory diseases.
    • Partner, AmLaw 100 firmFocused on licensing and strategic collaborations for life sciences and technology companies.

    • Harvard Law School, J.D.
    • Harvard Law School, J.D.

    • California
    • New York
    • California
    • New York

Greg's Insights

Firm News | 1 min read | 02.17.26

Crowell & Moring Advises GelMEDIX in $13 Million Seed Financing and Strategic Pharma Partnership

Boston – February 17, 2026: Crowell & Moring represented GelMEDIX, Inc., a biotechnology company focused on regenerative therapies for vision restoration, in the closing of its $13 million seed financing. The round was led by Safar Partners, with participation from HTL Biotechnology, Beacon Angels, TiE Boston Angels, Boston Harbor Angels, and additional investors. Alongside the financing, Crowell also advised on GelMEDIX’s first strategic collaboration with a global pharmaceutical company. Under the terms of the agreement, GelMEDIX will provide its hydrogel scaffold technology, which the partner will use in combination with several of its own cell lines to develop stem cell derived cell therapies....

View All Insights

Practices

Industries

Greg's Insights

Firm News | 1 min read | 02.17.26

Crowell & Moring Advises GelMEDIX in $13 Million Seed Financing and Strategic Pharma Partnership

Boston – February 17, 2026: Crowell & Moring represented GelMEDIX, Inc., a biotechnology company focused on regenerative therapies for vision restoration, in the closing of its $13 million seed financing. The round was led by Safar Partners, with participation from HTL Biotechnology, Beacon Angels, TiE Boston Angels, Boston Harbor Angels, and additional investors. Alongside the financing, Crowell also advised on GelMEDIX’s first strategic collaboration with a global pharmaceutical company. Under the terms of the agreement, GelMEDIX will provide its hydrogel scaffold technology, which the partner will use in combination with several of its own cell lines to develop stem cell derived cell therapies....

View All Insights